Dominari (DOMH) Competitors $6.42 +0.17 (+2.72%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DOMH vs. CBIO, VNDA, CDXS, IRWD, ACHV, SGMO, AGEN, FBIO, SABS, and CRISShould you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Crescent Biopharma (CBIO), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), Achieve Life Sciences (ACHV), Sangamo Therapeutics (SGMO), Agenus (AGEN), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), and Curis (CRIS). These companies are all part of the "biotechnology" industry. Dominari vs. Its Competitors Crescent Biopharma Vanda Pharmaceuticals Codexis Ironwood Pharmaceuticals Achieve Life Sciences Sangamo Therapeutics Agenus Fortress Biotech SAB Biotherapeutics Curis Dominari (NASDAQ:DOMH) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability. Which has more risk & volatility, DOMH or CBIO? Dominari has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Which has preferable earnings and valuation, DOMH or CBIO? Dominari has higher revenue and earnings than Crescent Biopharma. Dominari is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDominari$18.15M5.44-$14.70M-$2.37-2.71Crescent Biopharma$10K28,152.00-$37.88M-$34.93-0.41 Is DOMH or CBIO more profitable? Crescent Biopharma has a net margin of 0.00% compared to Dominari's net margin of -36.01%. Dominari's return on equity of -94.32% beat Crescent Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Dominari-36.01% -94.32% -78.21% Crescent Biopharma N/A -106.06%-86.60% Do institutionals & insiders have more ownership in DOMH or CBIO? 42.5% of Dominari shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 33.0% of Dominari shares are held by insiders. Comparatively, 4.0% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts recommend DOMH or CBIO? Crescent Biopharma has a consensus price target of $25.60, suggesting a potential upside of 77.78%. Given Crescent Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Crescent Biopharma is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Crescent Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Does the media favor DOMH or CBIO? In the previous week, Crescent Biopharma had 7 more articles in the media than Dominari. MarketBeat recorded 10 mentions for Crescent Biopharma and 3 mentions for Dominari. Dominari's average media sentiment score of 0.58 beat Crescent Biopharma's score of 0.41 indicating that Dominari is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dominari 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCrescent Biopharma beats Dominari on 10 of the 17 factors compared between the two stocks. Get Dominari News Delivered to You Automatically Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DOMH vs. The Competition Export to ExcelMetricDominariMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.12M$2.52B$5.69B$9.86BDividend YieldN/A1.67%4.01%4.02%P/E Ratio-2.715.2159.6622.54Price / Sales5.44731.65536.51112.00Price / CashN/A177.7737.7059.65Price / Book1.115.9810.576.59Net Income-$14.70M$32.94M$3.27B$265.83M7 Day Performance-0.93%-1.28%0.61%0.18%1 Month Performance32.37%2.31%5.43%2.13%1 Year Performance309.28%10.85%50.37%21.07% Dominari Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DOMHDominari0.5513 of 5 stars$6.42+2.7%N/A+293.1%$96.12M$18.15M-2.714Dividend AnnouncementCBIOCrescent Biopharma3.7348 of 5 stars$14.95+1.7%$25.60+71.2%N/A$292.27MN/A-0.4350News CoverageAnalyst ForecastVNDAVanda Pharmaceuticals4.4192 of 5 stars$4.65+0.8%$16.50+255.2%-10.8%$274.47M$198.77M-4.11290News CoverageCDXSCodexis3.808 of 5 stars$2.65-1.3%$11.00+315.9%-6.5%$238.76M$57.16M-3.19250Positive NewsIRWDIronwood Pharmaceuticals4.5627 of 5 stars$1.26-1.2%$4.94+293.6%-72.2%$203.85M$351.41M-25.09220ACHVAchieve Life Sciences2.0192 of 5 stars$3.24-2.3%$14.67+353.4%-29.9%$165.31MN/A-2.2220High Trading VolumeSGMOSangamo Therapeutics2.6726 of 5 stars$0.54-1.1%$4.50+727.2%-31.5%$164.43M$81.71M-1.88480Positive NewsAGENAgenus3.9768 of 5 stars$4.68+6.6%$15.50+231.2%-16.8%$149.11M$103.46M-0.65440News CoverageAnalyst ForecastFBIOFortress Biotech2.7621 of 5 stars$2.46+7.3%$16.50+571.3%+18.6%$73.48M$57.67M-2.35170High Trading VolumeSABSSAB Biotherapeutics2.6048 of 5 stars$2.18-1.4%$11.00+404.6%-28.3%$22.69M$1.32M-0.55140CRISCuris3.0409 of 5 stars$1.68+1.5%$17.00+914.9%-70.9%$20.94M$10.91M-0.3460 Related Companies and Tools Related Companies Crescent Biopharma Competitors Vanda Pharmaceuticals Competitors Codexis Competitors Ironwood Pharmaceuticals Competitors Achieve Life Sciences Competitors Sangamo Therapeutics Competitors Agenus Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Curis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DOMH) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dominari Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dominari With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access